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ABSTRACT
Objective We aimed to define the prognostic value of
the heart rate range during a 24 h period in patients
with chronic heart failure (CHF).
Methods Prospective observational cohort study of 791
patients with CHF associated with left ventricular systolic
dysfunction. Mode-specific mortality and hospitalisation
were linked with ambulatory heart rate range (AHRR;
calculated as maximum minus minimum heart rate using
24 h Holter monitor data, including paced and non-sinus
complexes) in univariate and multivariate analyses.
Findings were then corroborated in a validation cohort of
408 patients with CHF with preserved or reduced left
ventricular ejection fraction.
Results After a mean 4.1 years of follow-up, increasing
AHRR was associated with reduced risk of all-cause,
sudden, non-cardiovascular and progressive heart failure
death in univariate analyses. After accounting for
characteristics that differed between groups above and
below median AHRR using multivariate analysis, AHRR
remained strongly associated with all-cause mortality (HR
0.991/bpm increase in AHRR (95% CI 0.999 to 0.982);
p=0.046). AHRR was not associated with the risk of any
non-elective hospitalisation, but was associated with
heart-failure-related hospitalisation. AHRR was modestly
associated with the SD of normal-to-normal beats
(R2=0.2; p<0.001) and with peak exercise-test heart
rate (R2=0.33; p<0.001). Analysis of the validation
cohort revealed AHRR to be associated with all-cause
and mode-specific death as described in the derivation
cohort.
Conclusions AHRR is a novel and readily available
prognosticator in patients with CHF, which may reflect
autonomic tone and exercise capacity.
INTRODUCTION
Resting heart rate offers important prognostic
information in patients with chronic heart failure
(CHF), and its reduction is an important target
during the titration of mortality-reducing pharma-
cotherapy.1 2 It is also recognised that beat-to-beat
variations in heart rate offer additional prognostic
information, probably by reflecting autonomic dys-
function that contributes to the progression of
CHF.3 4 However, assessment of heart rate variabil-
ity (HRV) using ambulatory electrocardiography is
complex and limited to patients with sustained
periods of normal sinus rhythm,5 potentially
excluding more than half of the CHF population.
We therefore set out to define whether variation in
ambulatory heart rate during a 24 h period repre-
sents a simpler and more generalisable prognostic
marker.
METHODS
We conducted a prospective cohort study aiming to
define prognostic markers in patients with CHF,
associated with left ventricular systolic dysfunction
(LVSD), receiving contemporary evidence-based
therapies. Between June 2006 and December 2011,
all patients attending specialist cardiology clinics in
four UK hospitals were approached to participate.6
In total, 1091 recruited patients provided written
informed consent, and the Leeds West Research
Ethics Committee gave ethical approval; the investi-
gation conforms with the principles outlined in the
Declaration of Helsinki. All 791 patients with avail-
able ambulatory ECG data were included in this
analysis. Inclusion in the study required the pres-
ence of stable signs and symptoms of heart failure
for at least 3 months, and left ventricular ejection
fraction ≤45% on transthoracic echocardiography;
recruiting clinics reviewed adult patients only (age
≥18 years).
As described previously,7 details of medical
history were collected at recruitment, and symp-
tomatic status defined using the New York Heart
Association (NYHA) classification. Venous blood
was collected for measurement of electrolyte con-
centrations, assessment of renal function and haem-
atological parameters; these were performed in the
local hospital chemical pathology laboratories.
Estimated glomerular filtration rate was calculated
using the Modification of Diet in Renal Disease
method.8 Two-dimensional echocardiography was
performed according to British Society of
Echocardiography recommendations.7 Resting
heart rate was measured using 12-lead ECGs.
Use of diuretic therapy, ACE inhibitors (ACEi),
angiotensin receptor blockers and β-blockers were
collected at study recruitment. The prescribed daily
doses of β-blockers and diuretics were expressed
relative to the maximal licensed dose of bisoprolol
and furosemide, respectively.7 Receipt of cardiac
resynchronisation therapy or implantable
cardioverter-defibrillator was defined 6 months
after recruitment to account for device implant-
ation shortly after referral to the service. ‘Any
device therapy’ refers to patients with either a
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pacemaker or defibrillator. ‘Any atrial fibrillation or flutter’ was
defined as paroxysmal, persistent or permanent arrhythmia on
medical history, 12-lead or Holter electrocardiograph. Peak
oxygen uptake was measured as described,9 from the last 30 s of
a symptom-limited incremental peak exercise test on a treadmill
or stationary cycle, using breath-by-breath analysis
(Medgraphics, Minnesota, USA).
Ambulatory heart rate range and SD of normal-to-normal
beats analyses
Twenty-four hour ambulatory three-lead ECGs (Lifecard CF,
Spacelabs Healthcare, Washington, USA) were obtained during
normal, unrestricted, out-of-hospital activity.7 Recordings were
analysed with Delmar Reynolds Pathfinder or Spacelabs Sentinel
Systems by independent technical staff blinded to patient
characteristics. Each 24 h ECG recording was manually edited
to exclude incorrectly identified R waves and include unidenti-
fied R waves as determined at the automatic processing stage.
Ambulatory heart rate range (AHRR) was calculated as
maximum minus minimum heart rate during the period of ana-
lysis; automated mean heart rates for each minute of the day
(including all paced and non-sinus complexes) were used to
derive this data. For SD of normal-to-normal beats (SDNN) ana-
lyses, the standard Delmar Reynolds/Spacelabs RR interval
exclusion criteria were then applied to the manually edited
records. Specifically, RR intervals were excluded if: RR >2.0 s;
RR>3 SDs of the local 20 min interval; RR intervals <300 ms;
RR>120% of previous RR; RR <80% of previous RR. SDNN
was then determined using the proprietary Pathfinder software.
Ambulatory ECG data collected during a follow-up clinic visit
approximately 1 year later (available for 328 patients) were used
to define changes in ambulatory heart rate parameters.
Mortality and hospitalisation data
All patients were registered with the UK Office of Population
Censuses and Surveys, which provided details of death.
Classification criteria for the mode of death were defined
before the study commenced, based upon previous publica-
tions.10 At least two senior physicians reviewed each death cer-
tificate and gathered data as required from autopsy reports,
hospital notes and primary care records. Mode of death was
classified as: (1) sudden cardiac, if it occurred within 1 h of a
change in symptoms or during sleep or while the patient was
unobserved (defibrillator therapies were not included as a
proxy); (2) progressive HF, if death occurred after a documen-
ted period of symptomatic or haemodynamic deterioration; (3)
other cardiovascular death, if not occurring suddenly or in
association with progression of HF (eg, cerebrovascular acci-
dent); (4) non-cardiovascular death; and (5) unclassifiable,
where insufficient information was available to reach a firm
conclusion. Heart-failure-related hospitalisation was assessed as
described,7 using institutional clinical event databases detailing
all admissions in recruiting centres. Details of all non-elective
hospitalisations were also collected. Events were assessed
during the first year of recruitment and analysed as a binary
outcome.
Validation cohort
In order to assess the validity of our observations, analyses were
repeated in a second cohort of patients from the previously pub-
lished UK-HEART study.4 Briefly, 553 patients with CHF asso-
ciated with preserved or reduced ejection fraction were
recruited between December 1993 and April 1995, with the
aim to assess the prognostic value of HRV analysis; of these 408
had 24 h ECG data suitable for analysis. Patients with atrial
arrhythmias were excluded from this study due to their preclu-
sion of HRV analyses. No patients included in this analysis had
implantable cardiac devices.
Statistics
All analyses were conducted with SPSS V.21 (IBM, Armonk,
New York, USA). Continuous data are displayed as mean (SE of
mean), and categorical data are displayed as percentage
(number); normality of distribution was confirmed on skewness
testing. Continuous data are compared with unpaired Student’s
t tests, or analysis of variance (ANOVA) as appropriate, and cat-
egorical data with χ2 tests. Cox proportional hazards regression
analysis was used in univariate and multivariate mortality ana-
lyses (using all variables listed in table 3, without stepwise elim-
ination), and univariate hospitalisation analyses. Assessment of
partial residuals was used to confirm no deviation from the
assumption of proportional hazards. HRs are presented with
95% CIs. The relationship between AHRR and SDNN or
VO2max was defined with Pearson’s correlation test. Statistical
significance was defined as p<0.05.
RESULTS
Descriptive data for the 791 patients with available ambulatory
ECG data, divided into quartiles of AHRR (median 47; IQR
36–59), are provided in table 1. Lower AHRR was associated
with older age, lower resting heart rate, broader QRS interval,
lower haemoglobin, worse renal function, more ischaemic heart
disease, more diabetes, worse functional capacity, more device
therapy and less atrial dysrhythmia. Differences in AHRR
between these groups appeared to be predominantly due to dif-
ferences in maximum heart rate.
Mortality and hospitalisation analyses
After a mean follow-up period of 4.1 years (SE 0.07 years), a
total of 268 deaths occurred (95 progressive heart failure, 43
sudden, 104 non-cardiovascular, 17 other cardiovascular, 9 not
classifiable). As illustrated in figure 1, all-cause and cardiovascu-
lar mortality increased across quartiles of declining AHRR.
There was no interaction between the presence of atrial arrhyth-
mia and AHRR in predicting all-cause mortality (HR for no
atrial arrhythmia group 0.971 (95% CI 0.961 to 0.982); HR
for atrial arrhythmia group 0.984 (0.975 to 0.994)). There was
no interaction between the use of device therapy and AHRR in
predicting all-cause mortality (HR for no device group 0.981
(95% CI 0.972 to 0.989); HR for device group 0.981 (0.969 to
0.994)). Importantly, AHRR was also associated with risk of
progressive heart failure death, sudden death and non-
cardiovascular death in univariate analyses (table 2). After
accounting for characteristics that differed between AHRR quar-
tiles (with p≤0.002 to account for multiple tests) and bisoprolol
dose (as a potential confounder) using multivariate analysis,
AHRR remained associated with all-cause mortality (0.9%
reduction in mortality over the whole study period per beat/
minute increase in AHRR (95% CI 0% to 1.8%); p=0.046;
table 3).
During the first year of follow-up, 180 patients underwent
an unplanned hospitalisation, with 46 attributable to heart
failure. AHRR was not associated with the risk of any
non-elective hospitalisation (HR 0.993; 95% CI 0.985 to
1.001; p=0.079), but was associated with the risk of
heart-failure-related hospitalisation (HR 0.977; 95% CI 0.96
to 0.994; p=0.009).
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AHRR declined by 7.6% (49.8 (0.1) vs 46 (0.9) bpm;
p<0.001) between recruitment and follow-up (after 354 (7)
days) in the subset of 328 patients with repeat ambulatory ECG
data. Notably, β-blocker titration in this period was not
associated with either changes in AHRR or absolute AHRR at
follow-up (table 4). Follow-up AHRR remained associated with
all-cause mortality within this subgroup (HR 0.98; 95% CI
0.968 to 0.992; p=0.002).
Table 1 Cohort characteristics
Variable
AHRR <36
(n=181)
AHRR 36–46
(n=202)
AHRR 47–58
(n=197)
AHRR ≥59
(n=211)
p Value
(across all groups)
Age (years) 71.1 (0.8) 69.1 (0.8) 67.8 (0.9) 63.9 (0.9) <0.001
Resting heart rate (bpm) 70 (2) 71 (1) 73 (1) 80 (1) <0.001
Systolic blood pressure (mm Hg) 121 (2) 121 (2) 121 (2) 123 (2) 0.71
QRS interval (ms) 126 (2) 125 (2) 122 (2) 116 (2) 0.01
Haemoglobin (g/dL) 129 (1) 136 (1) 136 (1) 142 (1) <0.001
Sodium (mmol/L) 139 (1) 139 (1) 140 (1) 140 (1) 0.12
eGFR (mL/Kg/1.73 m2) 49 (1) 54 (1) 56 (1) 61 (1) <0.001
LV ejection fraction (%) 33 (1) 32 (1) 32 (1) 31 (1) 0.58
Minimum 24 h heart rate (bpm) 59 (1) 58 (1) 56 (1) 57 (1) 0.37
Maximum 24 h heart rate (bpm) 86 (1) 98 (1) 108 (1) 133 (1) <0.001
Ambulatory heart rate range (bpm) 28 (1) 41 (1) 52 (1) 76 (1) <0.001
Male sex (% (n)) 73.5 (133) 73.8 (149) 74.1 (146) 73.5 (155) 0.99
Ischaemic aetiology (% (n)) 79 (143) 69.3 (140) 66 (130) 42.2 (89) <0.001
NYHA class 0.12
I 14.4 (26) 17.9 (36) 25.4 (50) 24.3 (51)
II 48.1 (87) 46.3 (93) 39.6 (78) 48.1 (101)
III 35.4 (64) 33.3 (67) 33.5 (66) 26.7 (56)
IV 2.2 (4) 2.5 (5) 1.5 (3) 1 (2)
Any device therapy (% (n)) 36.5 (66) 32.2 (65) 24.9 (49) 20.4 (43) 0.002
Cardiac resynchronisation (% (n)) 28.7 (52) 28.7 (58) 23.4 (46) 19 (40) 0.06
Implantable defibrillator (% (n)) 18.2 (33) 13.4 (27) 8.6 (17) 9 (19) 0.01
Any atrial fibrillation or flutter (% (n)) 22 (39) 23.9 (48) 30.4 (58) 48.8 (100) <0.001
Non-sustained VT (% (n)) 36.9 (65) 35.8 (72) 37.6 (71) 47.1 (96) 0.08
Diabetes (% (n)) 40.9 (74) 28.7 (58) 20.8 (41) 14.7 (31) <0.001
β-blocker use (% (n)) 82.3 (149) 81 (162) 77.2 (152) 76.6 (160) 0.42
β-blocker dose (mg bisoprolol/day) 4.0 (0.3) 3.4 (0.2) 3.6 (0.2) 3.1 (0.2) 0.088
ACEi/ARB use (% (n)) 86.7 (157) 87 (174) 91.4 (180) 87.6 (183) 0.45
MRA use (% (n)) 45.9 (83) 43.5 (87) 41.1 (81) 32.1 (67) 0.03
Furosemide dose (mg/day) 66 (4) 56 (4) 52 (4) 40 (3) <0.001
AHRR, ambulatory heart rate range; ACEi, ACE inhibitors; ARB, angiotensin receptor blockers; eGFR, estimated glomerular filtration rate; LV, left ventricular; MRA, mineralocorticoid
receptor antagonist; NYHA, New York Heart Association; VT, ventricular tachycardia.
Figure 1 All-cause mortality and AHRR. Kaplan–Meier curves illustrating all-cause (A) and cardiovascular (B) mortality according to quartiles of
AHRR (p<0.001 by log-rank analysis). AHRR, ambulatory heart rate range.
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Association of AHRR with functional capacity
To explore what AHRR might tell us about patients with CHF,
exploratory association analyses were performed. AHRR falls
progressively as NYHA functional impairment classification rises
(p=0.001 by ANOVA). Within the 98 patients in our AHRR
cohort referred for cardiopulmonary exercise testing, there was
very weak correlation between AHRR and VO2max (R
2=0.06
(95% CI 0.001 to 0.20); p=0.015). However, differences in
peak heart rate during cardiopulmonary exercise testing
accounted for one-third of variation in AHRR (figure 2A;
R2=0.33 (95% CI 0.1 to 0.55); p<0.001).
Association of AHRR with HRV
Given the influence of the autonomic nervous system upon
heart rate variation, we next explored the correlation between
AHRR and SDNN. Data available for a subgroup of 199
patients collected as part of a separate substudy were included
in this analysis; by definition, these patients were selected by
virtue of being in sinus rhythm for sustained periods of moni-
toring. AHRR modestly correlated with SDNN (figure 2B;
R2=0.2 (0.08 to 0.34); p<0.001). Interestingly, when both
AHRR and SDNN were included in a multivariate analysis
using these 199 highly selected patients, only SDNN was asso-
ciated with risk of all-cause mortality (HRs (95% CI) SDNN
0.99 (0.981 to 0.998); AHRR 0.994 (0.976 to 1.012)).
Validation cohort analyses
To assess the validity and generalisability of our observations,
we conducted analyses in a cohort of patients with CHF asso-
ciated with reduced or preserved left ventricular ejection frac-
tion recruited in the late 1990s.4 The UK-HEART study aimed
to define the prognostic role of HRV in CHF, and so only
recruited patients without sustained atrial arrhythmia or other
factors associated with autonomic dysfunction (diabetes, end-
stage renal failure). Of the 553 patients recruited, 408 had 24 h
ECG data of suitable quality to assess HRV, and so were
included in this analysis. Mean age was 62.1 years (SE of mean
0.5), 74.5% were male, 77.9% had ischaemic aetiology and
reduced left ventricular ejection fraction (below 50%) was noted
in 64.8%. While 83.1% of patients received ACE inhibitor
therapy, only 8.1% received β-blockers, in keeping with the
study era. No patients had implantable cardiac devices. Hence,
this cohort statistically differs (p<0.05) with our principal study
cohort in terms of age, β-blocker use, ejection fraction,
comorbidity and arrhythmia burden, allowing us to assess
whether the prognostic value of AHRR transfers to more
diverse CHF populations.
After a mean 3 years’ follow-up, 144 patients had died (59
progressive heart-failure-associated deaths, and 49 sudden
deaths). In univariate analyses, AHRR remained associated with
the risk of all-cause death (HR 0.973 (95% CI 0.962 to 0.984);
p<0.001), progressive heart failure death (0.956 (0.939–0.974);
p<0.001) and sudden death (0.981 (0.963 to 0.999);
p=0.037). AHRR was associated with all-cause mortality in sub-
groups with reduced (n=261) or preserved (n=126) LV ejection
fraction (figure 3). In a multivariate analysis identical to that
presented in table 3 (other than without atrial arrhythmia, any
device therapy or diabetes, since these were not present), AHRR
remained strongly associated with the risk of all-cause death
(0.968 (0.956 to 0.981); p<0.001). AHRR fell progressively
with increasing NYHA class (p<0.001 by ANOVA), and corre-
lated significantly with SDNN (R2=0.28 (0.19 to 0.36);
p<0.001).
DISCUSSION
In this manuscript, we provide the first ever assessment of the
prognostic value of the daily heart rate range in patients with
CHF. To summarise, AHRR is associated with all-cause and
mode-specific death, along with heart-failure-related hospitalisa-
tion; even after accounting for potentially confounding prognos-
tic factors, AHRR remains associated with all-cause mortality.
Notably, the relationship between AHRR and mortality per-
sisted when assessed in an independently recruited cohort with
CHF, within subgroups with either reduced or preserved left
ventricular ejection fraction. The factors underpinning the asso-
ciation between AHRR and CHF outcome remain unclear,
although our exploratory analyses indicate associations between
Table 2 Univariate mortality analyses
95% CI of HR
Mode of death HR Low High p Value
All cause 0.981 0.974 0.988 <0.001
Progressive heart failure 0.981 0.969 0.993 0.002
Sudden 0.972 0.954 0.990 0.003
Non-cardiovascular 0.981 0.97 0.993 0.001
HRs associated with a 1 bpm increase in AHRR
AHRR, ambulatory heart rate range.
Table 3 Multivariate analysis of all-cause mortality
95% CI of HR
Variable HR Low High p Value Wald
Age (per year) 1.048 1.032 1.065 <0.001 34.2
Diabetes 1.75 1.31 2.35 <0.001 14.2
Haemoglobin (per 10 g/L) 0.87 0.8 0.95 0.002 9.5
Resting heart rate (per bpm) 1.011 1.004 1.019 0.004 8.4
Ischaemic cardiomyopathy 1.57 1.11 2.23 0.011 6.5
AHRR (per bpm) 0.991 0.982 0.999 0.046 4
Any atrial fibrillation or flutter 1.34 0.99 1.82 0.06 3.5
Bisoprolol daily dose (per mg) 0.97 0.92 1.01 0.12 2.4
Any device therapy 1.11 0.83 1.49 0.48 0.5
eGFR (per mL/Kg/1.73 m2) 1.003 0.994 1.013 0.49 0.5
AHRR, ambulatory heart rate range; eGFR, estimated glomerular filtration rate.
Table 4 Changes in ambulatory heart rate range (AHRR)
according to β-blocker titration
β-blocker
dose
reduced
(n=30)
β-blocker
unchanged
(n=119)
β-blocker
increased
(n=170) p Value
Change in bisoprolol
dose (mg/day)
−3.8 (0.5) 0 (0) 4.1 (0.2) <0.001
Bisoprolol dose at
follow-up (mg/day)
0.9 (0.3) 4.5 (0.3) 6.4 (0.2) <0.001
Change in AHRR
(bpm)
−2.8 (3.3) −0.7 (1.5) −5.1 (1.5) 0.13
AHRR at follow-up
(bpm)
42.5 (2.5) 45.9 (1.5) 46.5 (0.9) 0.5
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AHRR and both functional capacity and autonomic
dysfunction.
Heart rate and prognosis in CHF
It is well established that elevated resting heart rate represents
an important adverse prognostic factor, and also a therapeutic
target, in patients with CHF associated with LVSD.1 2
Moreover, a number of studies have suggested that the magni-
tude of heart rate reduction in response to β-blocker therapy is
more important than the achieved dose of these agents in pre-
dicting outcome.11 12 Importantly, researchers have long recog-
nised the potentially useful additional prognostic data that can
be derived from the dynamic properties of the heart rate,
including, for example: chronotropic response to exercise,13 14
heart rate recovery after exercise15 16 and HRV.3 4
SDNN, a marker of beat-to-beat variation in cycle length, is
perhaps the best established measure of HRV in clinical
research, and is recognised as a powerful prognosticator.
However, it is also limited by the requirement of prolonged
high-quality ECGs during uninterrupted sinus rhythm,
essentially excluding more than half of a typical CHF popula-
tion.5 Moreover, its derivation and interpretation is relatively
complex, meaning that it is generally not applied in routine clin-
ical practice. It is therefore interesting that AHRR is simple to
derive in all patients within an unselected CHF cohort, and yet
robustly predicts adverse outcome, possibly by reflecting some
of the autonomic dysfunction we infer from SDNN. We feel
that this simplicity may be critical in translating the use of
AHRR as part of our prognostic repertoire in clinical practice,
and allowing rapid assessment of its potential use in other set-
tings, for example in implanted device monitoring.
What does AHRR tell us?
While the data we present clearly suggest AHRR can assist in
the prediction of mode-specific mortality and hospitalisation,
we cannot offer an assessment of whether it acts as a marker or
a mediator of adverse prognosis. However, our exploratory ana-
lyses suggest that AHRR is associated with important biological
phenomena, which may themselves influence CHF outcome.
First, we have demonstrated that as functional capacity and peak
Figure 2 Correlative analyses. Scatter plots illustrating correlation between AHRR and: (A) maximal cardiopulmonary exercise test heart rate: R2
0.33 (p<0.001); (B) SD of normal-to-normal beats: R2 0.2 (p<0.001). AHRR, ambulatory heart rate range; SDNN, SD of normal-to-normal beats.
Figure 3 All-cause mortality in validation cohort. Kaplan–Meier curves illustrating all-cause mortality above or below median AHRR in patients
with: (A) CHF-PEF; (B) CHF-REF (both p<0.05 by log-rank analysis). AHRR, ambulatory heart rate range; CHF-PEF, chronic heart failure with
preserved ejection fraction; CHF-REF, chronic heart failure with reduced ejection fraction.
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exercise heart rate decline, so too does AHRR. However, only a
relatively small proportion of the variation in AHRR could be
explained by peak exercise heart rate. Moreover, it remains
unclear whether the link between AHRR and NYHA class is
simply a reflection of physical inactivity, or whether this tells us
something more about the disease process per se. A second bio-
logical link was between AHRR and autonomic tone, as assessed
using SDNN—lower SDNN (an adverse prognostic feature) was
noted as AHRR decreased. While it is interesting that a multi-
variate analysis including SDNN and AHRR suggested that only
SDNN was associated with the risk of all-cause mortality, this
analysis is limited by selection bias entailed in acquiring SDNN
data. However, these analyses do add further support to the
suggestion that autonomic tone is associated with AHRR, and
notably diabetes is substantially more common in people with
low AHRR. Interestingly, recently published data suggest that
regular physical activity is also associated with increased HRV in
older adults without CHF, potentially linking the phenomena
we noted to be associated with AHRR.17
Study limitations
While our observations are novel and have the potential to be
readily adopted in routine clinical practice, they also have limita-
tions. Our study population is relatively small, although it is
important to note that this allowed us to phenotype our patients
in more detail than is generally possible in large clinical trials
(eg, SDNN analysis). It will therefore be important to further
validate our findings in larger and more diverse CHF popula-
tions, although the recapitulation of our observations in a
second CHF cohort adds significant strength to our findings.
The observational nature of the study also prevents us from
drawing any firm conclusions regarding the biological phenom-
ena controlling AHRR, which is important in understanding its
link to outcomes. Moreover, we are likely not to have accounted
for all confounding factors in our multivariate analyses, but
hope that these at least demonstrate that AHRR adds value to
other readily available clinical data. In particular, we are unable
to comment on NT-proBNP in our population or the value of
AHRR as part of an established prognostic model. Finally, it
will also be important to understand whether properties of the
daily heart rate profile beyond its range offer further value.
Remaining questions
As discussed earlier in this section, our data raise many other
questions regarding the value of measuring AHRR during the
assessment and management of patients with CHF. First, it will
be important to assess the incremental value of AHRR beyond
established prognostic scores (eg, the Seattle Heart Failure
Model18). However, many factors included in established prog-
nostic scores are already accounted for in our multivariate ana-
lysis, suggesting that AHRR may offer additional prognostic
value. It will also be interesting to define how short-term and
long-term changes in AHRR are associated with CHF events; this
may suggest a role for AHRR monitoring by implantable cardiac
devices, akin to previous data suggesting a role for SDNN moni-
toring.19 Finally, it will be interesting to explore whether AHRR
during sleep offers prognostic value, and whether physical activ-
ity monitoring offers complementary data.
CONCLUSIONS
AHRR is a simple to derive index of HRV during a 24 h period,
which is associated with both indices of exercise physiology and
autonomic function, and offers important prognostic informa-
tion, independent of other established prognostic factors.
Key messages
What is already known on this subject?
Resting heart rate and indices of heart rate variability are
powerful predictors of adverse outcome in patients with chronic
heart failure. However, most indices of heart rate variability are
complex to derive and exclude patients without sustained
periods of sinus rhythm.
What might this study add?
The heart rate range during 24 h of ambulatory
electrocardiography is associated with mode-specific mortality
and hospitalisation in patients with heart failure, irrespective of
left ventricular function or cardiac rhythm. After accounting for
potential confounding factors, each one beat increase in heart
rate range is associated with a 0.9% relative reduction in
all-cause mortality.
How might this impact on clinical practice?
While traditional heart rate variability indices offer valuable
prognostic data, they are rarely applied in clinical practice due
to complex analytical techniques and exclusion of patients with
atrial arrhythmias and paced rhythms. Ambulatory heart rate
range may circumvent these issues and offer other novel
opportunities in the monitoring of patients with implantable
cardiac devices.
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